Is Privia Health Group, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Privia Health Group, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company is considered overvalued, with a P/E ratio of 181, a Price to Book Value of 4.29, and an EV to EBITDA of 82.17, all of which are substantially higher than typical industry benchmarks.
In comparison to its peers, Privia Health's P/E ratio is notably high, with Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59, both categorized as fairly valued. Additionally, Lincoln National Corp. is rated very attractive with a P/E of 6.96, further emphasizing Privia's overvaluation. Despite its strong recent performance, with a 1Y return of 38.45% compared to the S&P 500's 14.08%, the elevated valuation ratios suggest that the stock may not be a sustainable investment at current levels.